Exelixis vs Moderna
EXEL and MRNA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EXEL and MRNA compare
Moderna is the larger company, worth 5.1 times as much as Exelixis ($88.5B against $17.2B).
Exelixis grew revenue faster over the last twelve months (9.1% versus −27.6% for Moderna).
Exelixis keeps more of each dollar of sales as profit, with a net margin of 35.5% compared with −141% at Moderna.
Exelixis scores higher on the StockData Score (17 against 5 for Moderna), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EXEL | MRNA |
|---|---|---|
| Size and price | ||
| Market cap | $17.2B | $88.5B |
| Share price | $69.39 | $221.72 |
| Change, 1 year | 76.0% | 798% |
| Change, 5 years | 258% | −6.4% |
| Beta (5Y) | 0.74 | 1.11 |
| Employees | 1,077 | 4,700 |
| StockData Score | ||
| Total score | 17 (better) | 5 |
| Valuation score | 2 (better) | 0 |
| Growth score | 3 (better) | 1 |
| Performance score | 6 (better) | 1 |
| Health score | 6 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 20.8× | – |
| P/S | 6.9× (better) | 39.7× |
| P/B | 9.4× (better) | 13.1× |
| EV/EBITDA | 15.8× | – |
| P/FCF | 14.8× | – |
| PEG | 0.29 | – |
| FCF yield | 6.8% (better) | −1.4% |
| Fair value | $64.67 | $33.24 |
| Margin of safety | −7.3% (better) | −567% |
| Growth | ||
| Revenue growth (TTM) | 9.1% (better) | −27.6% |
| Revenue growth, 5Y average | 18.6% | 19.3% (better) |
| Net income growth (TTM) | 30.6% | – |
| EPS growth (TTM) | 40.9% | – |
| EPS growth, 5Y average | 51.4% | – |
| Profitability | ||
| Gross margin | 96.3% (better) | 23.4% |
| Operating margin | 40.2% (better) | −149% |
| Net margin | 35.5% (better) | −141% |
| FCF margin | 46.5% (better) | −55.8% |
| Return on equity | 44.3% (better) | −39.0% |
| Return on invested capital | 75.0% (better) | −80.9% |
| Financial health | ||
| Debt / equity | 0.00 | 0.09 (better) |
| Current ratio | 3.21 (better) | 2.29 |
| Altman Z-score | 17.78 (better) | 12.86 |
| Piotroski F-score | 7 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | 7.3% | – |
| Shareholder yield | 7.3% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 105% | 79.9% |
| Held by insiders | 9.7% | 5.6% |
| Insider net buying, 12 months | −$41.1M (better) | −$64.6M |
| Short interest, % of float | 12.6% | 8.2% |
Go deeper
- EXEL stock overview
- EXEL income statement
- EXEL valuation and score
- MRNA stock overview
- MRNA income statement
- MRNA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.